PLC-β2 monitors the drug-induced release of differentiation blockade in tumoral myeloid precursors

Journal of Cellular Biochemistry

Volumn 98, Issue 1, 2006, Pages 160-173

  Brugnoli, Federica ^a   Bovolenta, Matteo ^a   Benedusi, Mascia ^a   Miscia, Sebastianó ^b   Capitani, Silvano ^a,c   Bertagnolo, Valeria ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Institute of Human Anatomy   (Italy)

Author keywords

Acute promyelocytic leukemia (APL); AS2O3; ATRA; NB4; Phospholipase C 2 (PLC 2)

Indexed keywords

PHOSPHOLIPASE C BETA2; RETINOIC ACID; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; GROWTH INHIBITOR; ORGANOARSENIC DERIVATIVE; OXIDE; PHOSPHOLIPASE C BETA; PLCB2 PROTEIN, HUMAN;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; RNA INTERFERENCE; BIOSYNTHESIS; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; MYELOID PROGENITOR CELL; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ARSENICALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; ENZYME INDUCTION; GROWTH INHIBITORS; HUMANS; MYELOID PROGENITOR CELLS; OXIDES; PHOSPHOLIPASE C BETA; TRETINOIN;

EID: 33645959829     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20749     Document Type: Article

References (35)

1. Avvisati G, Tallman MS. 2003. All-trans retinoic acid in acute promyelocytic leukemia. Best Pract Res Clin Haematol 16:419-432.
2. Bertagnolo V, Marchisio M, Capitani S, Neri LM. 1997. Intranuclear translocation of phospholipase C beta2 during HL-60 myeloid differentiation. Biochem Bioph Res Co 235:831-837.
3. Bertagnolo V, Marchisio M, Volinia S, Caramelli E, Capitani S. 1998. Nuclear association of tyrosine-phosphorylated Vav to phospholipase C-γ1 and phosphoinositide 3-kinase during granulocytic differentiation of HL-60 cells. FEBS Lett 441:480-484.
4. Bertagnolo V, Neri LM, Marchisio M, Mischiati C, Capitani S. 1999. Phosphoinositide 3-kinase activity is essential for ATRA-induced granulocytic differentiation of HL-60 cells. Cancer Res 59:542-546.
5. Bertagnolo V, Marchisio M, Brugnoli F, Bavelloni A, Boccafogli L, Colamussi ML, Capitani S. 2001. Requirement of tyrosine-phosphorylated Vav for morphological differentiation of all-trans-retinoic acid-treated HL-60 cells. Cell Growth Differ 12:193-200,
6. Bertagnolo V, Marchisio M, Pierpaoli S, Colamussi ML, Brugnoli F, Visani G, Zauli G, Capitani S. 2002. Selective up-regulation of phospholipase C-beta2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors. J Leukoc Biol 71:957-965.
7. Bertagnolo V, Brugnoli F, Marchisio M, Celeghini C, Carini C, Capitani S. 2004. Association of PI 3-K with tyrosine phosphorylated Vav is essential for its activity in neutrophil-like maturation of myeloid cells. Cell Signal 16:423-433.
8. 3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353.
9. Denis FM, Benecke A, di Gioia Y, Touw IP, Cayre YE, Lutz PG. 2005. Pram-1 potentiates arsenic trioxide-induced Jnk activation. J Biol Chem 11:9043-9048.
10. Evens A, Tallman M, Gartenhaus R. 2004. The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future. Leuk Res 28:891-900.
11. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H. 1998. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91: 4300-4310.
12. Iiri T, Homma Y, Ohoka Y, Robishaw JD, Katada T, Bourne HR. 1995. Potentiation of Gi-mediated phospholipase C activation by retinoic acid in HL-60 cells. Possible role of G gamma 2. J Biol Chem 270:5901-5908.
13. Jing Y. 2004. The PML-RAR alpha fusion protein and targeted therapy for acute promyelocytic leukemia. Leuk Lymphoma 45:639-648.
14. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, Waxman S. 2001. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97:264-269.
15. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H. 1999. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189:1043-1052.
16. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. 1991. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77:1080-1086.
17. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. 2003. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The M. D. Anderson experience. Cancer 97: 2218-2224.
18. Marchisio M, Bertagnolo V, Colamussi ML, Capitani S, Neri LM. 1998. Phosphatidylinositol 3-kinase in HL-60 nuclei is bound to the nuclear matrix and increases during granulocytic differentiation. Biochem Bioph Res Co 253:346-351.
19. Melnick A, Licht JD. 1999. Deconstructing a disease: RARα, its fusion partners, and their roles in pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215.
20. Miller WH, Jr., Waxman S. 2002. Differentiation induction as a treatment for hematologic malignancies. Oncogene 21:3496-3506.
21. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. 2002. Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903.
22. Parmar S, Tallman MS. 2003. Acute promyelocytic leukaemia: A review. Exp Op Pharmacoter 4:1379-1392.
23. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH, Jr. 1998. Arsenic trioxide as an inducer of apoptosis and loss PML/RARα in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124-133.
24. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101:5328-5335.
25. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. 2002. Advances in the management of acute promyelocytic leukemia and others hematologic malignancies with arsenic trioxide. Oncologist 7:1-13.
26. Soignet SL. 2001. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6:11-16.
27. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP, Jr. 1998. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348.
28. Tallman MS. 2004. Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 41:27-32.
29. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. 1997. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028.
30. Tallmann MS, Nabhan C, Feusner JH, Rowe JM. 2002. Acute promyelocytic leukemia: Evolving therapeutic strategies. Blood 99:759-767.
31. Wang G, Li W, Cui J, Gao S, Yao C, Jiang Z, Song Y, Yuan CJ, Yang Y, Liu Z, Cai L. 2004. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 22:63-71.
32. Warrell RP, Jr., de Thé H, Wang ZY, Degos L. 1993. Acute promyelocytic leukemia. N Engl J Med 329:177-189.
33. Zauli G, Visani G, Bassini A, Caramelli E, Ottaviani E, Bertolaso L, Bertagnolo V, Borgatti P, Capitani S. 1996. Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid. Br J Haematol 93:542-550.
34. Zhu J, Lallemand-Breitenbach V, de Thè H. 2001. Pathways of retinoic acid or arsenic trioxide-induced PML/ RARα catabolism, role of oncogene degradation in disease remission. Oncogene 20:7257-7265.
35. 2+- dependent protein kinase activity and protein phosphorylation patterns in the differentiation of human promyelocytic leukemia cell line HL-60. Cancer Res 5:5159-5164.